http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 15 Apr 2025 01:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/jp..kyoto" idsrc="xmltag.org" >KYOTO, Japan</location></span>, <span class="legendSpanClass"><chron>April 15, 2025</chron></span> /PRNewswire/ -- <span>Rege Nephro Co., Ltd.</span> (Headquarter: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; Chief Executive Officer: <person>Akifumi Morinaka</person>) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on <chron>February 26, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html Tue, 15 Apr 2025 01:20:00 -0400 A.15263444 O.50982899 SYRS http://www.streetinsider.com/Press+Releases/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/jp..kyoto" idsrc="xmltag.org" >KYOTO, Japan</location></span>, <span class="legendSpanClass"><chron>April 15, 2025</chron></span> /PRNewswire/ -- <span>Rege Nephro Co., Ltd.</span> (Headquarter: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; Chief Executive Officer: <person>Akifumi Morinaka</person>) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on <chron>February 26, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html Tue, 15 Apr 2025 01:20:00 -0400 A.15263444 O.50982899 SYRS http://www.streetinsider.com/Press+Releases/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/jp..kyoto" idsrc="xmltag.org" >KYOTO, Japan</location></span>, <span class="legendSpanClass"><chron>April 15, 2025</chron></span> /PRNewswire/ -- <span>Rege Nephro Co., Ltd.</span> (Headquarter: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; Chief Executive Officer: <person>Akifumi Morinaka</person>) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on <chron>February 26, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html Tue, 15 Apr 2025 01:20:00 -0400 A.15263444 O.50982899 SYRS http://www.streetinsider.com/PRNewswire/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/jp..kyoto" idsrc="xmltag.org" >KYOTO, Japan</location></span>, <span class="legendSpanClass"><chron>April 15, 2025</chron></span> /PRNewswire/ -- <span>Rege Nephro Co., Ltd.</span> (Headquarter: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; Chief Executive Officer: <person>Akifumi Morinaka</person>) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on <chron>February 26, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html Tue, 15 Apr 2025 01:20:00 -0400 A.15263444 O.50982899 SYRS http://www.streetinsider.com/PRNewswire/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/jp..kyoto" idsrc="xmltag.org" >KYOTO, Japan</location></span>, <span class="legendSpanClass"><chron>April 15, 2025</chron></span> /PRNewswire/ -- <span>Rege Nephro Co., Ltd.</span> (Headquarter: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; Chief Executive Officer: <person>Akifumi Morinaka</person>) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on <chron>February 26, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html Tue, 15 Apr 2025 01:20:00 -0400 A.15263444 O.50982899 SYRS http://www.streetinsider.com/PRNewswire/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/jp..kyoto" idsrc="xmltag.org" >KYOTO, Japan</location></span>, <span class="legendSpanClass"><chron>April 15, 2025</chron></span> /PRNewswire/ -- <span>Rege Nephro Co., Ltd.</span> (Headquarter: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; Chief Executive Officer: <person>Akifumi Morinaka</person>) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on <chron>February 26, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rege+Nephro+Acquires+Tamibarotene-Related+Assets+from+Syros+Pharmaceuticals+for+U.S.+Clinical+Trials/24637867.html Tue, 15 Apr 2025 01:20:00 -0400 A.15263444 O.50982899 SYRS http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./24561189.html si-local-file:///var/storage/secattach/20250327/24561189.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./24561189.html Thu, 27 Mar 2025 18:17:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./24561189.html si-local-file:///var/storage/secattach/20250327/24561189.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./24561189.html Thu, 27 Mar 2025 18:17:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Syros+Pharmaceuticals%2C+++++++++++++++/24529996.html si-local-file:///var/storage/secattach/20250320/24529996.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Syros+Pharmaceuticals%2C+++++++++++++++/24529996.html Thu, 20 Mar 2025 17:01:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Syros+Pharmaceuticals%2C+++++++++++++++/24529996.html si-local-file:///var/storage/secattach/20250320/24529996.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Syros+Pharmaceuticals%2C+++++++++++++++/24529996.html Thu, 20 Mar 2025 17:01:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Fanucci+Marsha/24503829.html si-local-file:///var/storage/secattach/20250314/24503829.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Fanucci+Marsha/24503829.html Fri, 14 Mar 2025 16:43:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Fanucci+Marsha/24503829.html si-local-file:///var/storage/secattach/20250314/24503829.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Syros+Pharmaceuticals%2C+++++++++++++++++Filed+by%3A+Fanucci+Marsha/24503829.html Fri, 14 Mar 2025 16:43:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487631.html si-local-file:///var/storage/secattach/20250312/24487631.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487631.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487631.html si-local-file:///var/storage/secattach/20250312/24487631.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487631.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487632.html si-local-file:///var/storage/secattach/20250312/24487632.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487632.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487632.html si-local-file:///var/storage/secattach/20250312/24487632.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487632.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487639.html si-local-file:///var/storage/secattach/20250312/24487639.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487639.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487639.html si-local-file:///var/storage/secattach/20250312/24487639.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487639.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487645.html si-local-file:///var/storage/secattach/20250312/24487645.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487645.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487645.html si-local-file:///var/storage/secattach/20250312/24487645.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487645.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487652.html si-local-file:///var/storage/secattach/20250312/24487652.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487652.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487652.html si-local-file:///var/storage/secattach/20250312/24487652.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487652.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487653.html si-local-file:///var/storage/secattach/20250312/24487653.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487653.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487653.html si-local-file:///var/storage/secattach/20250312/24487653.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487653.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487664.html si-local-file:///var/storage/secattach/20250312/24487664.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Syros+Pharmaceuticals%2C+++++++++++++++/24487664.html Wed, 12 Mar 2025 06:02:00 -0400 O.15696008 SYRS